Traditional recipes

The FDA Wants to Know All About Your Nutella Habits

The FDA Wants to Know All About Your Nutella Habits

The chocolate-hazelnut spread is more than just a dessert topping

Nutella is a popular option to put on breakfast toast.

Nutella wants to break-free of its “dessert topping” label and be placed in the category similar to honey, jam, and jelly, according to Bloomberg. Food and Drug Administration wants to monitor Americans’ consumption of the spread to determine if it should be granted entry into that category.

Ferrero, Nutella’s parent company, began a petition to change the definition of the product in 2014, claiming it is no longer considered a dessert-only option, Grub Street reported. The petition claimed that in 2012, 74 percent of Nutella consumed in the U.S. was put on bread in 2012, as opposed to only 2 percent used on ice cream. The spread has also made its way to breakfast items such as toast, pancakes, and crêpes.

The FDA recently released a document to gather information for 60 days to see whether the data received matches Ferrero’s claim.

By changing the classification of Nutella, the company can change its nutrition labels. It can cut the current serving size of two tablespoons in half, so as to have a serving size of 100 calories that contains between five to six grams of fat per tablespoon.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.


INDUSTRY NEWS

Today, the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE) launched the "Send Your Oncology Research Questions to FDA" crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA's scientific staff.

Traditionally, FDA's scientists have used pooled analyses to deepen understanding of efficacy of approved drugs, investigate relationships between different clinical endpoints used in regulatory submissions, and explore the potential for external controls to provide context for single arm trials. However, OCE wants to hear the questions you would like addressed with pooled analysis.

After this challenge ends, OCE may select questions for possible future analyses by FDA staff. If your research question is selected for further analysis, you will be recognized on the OCE website and social media, invited to a discussion with OCE leadership and honored at a virtual award ceremony.

Please note that individuals who submit research questions will not obtain access to data or collaborate in any new research studies initiated by FDA.

Submissions to this challenge must be received by June 4, 2021. Visit OCE's Crowdsourcing site for more information about how to submit your research idea to the challenge and examples of ideas that may be considered. All submissions and discussions on the site will be moderated by FDA staff.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry.